Hyperliquid Strategies and Sonnet BioTherapeutics Complete Business Combination.

miércoles, 3 de diciembre de 2025, 8:15 am ET1 min de lectura
PURR--
SONN--

Hyperliquid Strategies Inc. and Sonnet BioTherapeutics Holdings Inc. have completed their business combination. The combined company's common stock is expected to start trading on Nasdaq on December 3 under the ticker "PURR." The deal was approved by Sonnet's stockholders on December 2.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios